Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer

In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.